Skip to main content
OpenTrials
Completed

NCT Number: NCT04376593

PET/CT Imaging in COVID-19 Patients

This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Sars-CoV-2 Infection Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of California Davis

Sacramento, California, 95817, United States

About this study

The goal of the study is to to acquire 18F-αvβ6-BP PET/CT images in patients diagnosed with SARS CoV2 and to demonstrate the ability of 18F-αvβ6-BP to detect lung damage.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women age ≥ 18 yrs
  • Diagnosed with SARS CoV2
  • Must have 2 sequential COVID negative tests prior to each scan
  • Must have no previous lung disease prior to SARS CoV2 infection
  • Lung image (Xray or CT) taken during infectious/ diagnosis period
  • Will sign the IRB-approved consent form
  • Able to remain motionless for up to 30-60 minutes per scan.

Exclusion criteria

  • Life expectancy <3 mo
  • Women who are pregnant or breast-feeding
  • Patients who cannot undergo PET/CT scanning because of weight limits(>350lbs)
  • Lack of availability for follow-up assessments
  • Re-infection with SARS CoV2 between scan sessions
  • Other active infectious respiratory illness

Treatment and study plan

18F-αvβ6-BP

Drug

Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs).

Primary outcomes

  1. Administration of 18F-αvβ6-BP

    Time frame: baseline

    Completion of administration of 18F-αvβ6-BP in SARC CoV2 patients

  2. Administration of 18F-αvβ6-BP

    Time frame: 3 months

    Completion of administration of 18F-αvβ6-BP in SARC CoV2 patients

  3. Administration of 18F-αvβ6-BP

    Time frame: 6 months

    Completion of administration of 18F-αvβ6-BP in SARC CoV2 patients

Secondary outcomes

  1. Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage

    Time frame: baseline

    Uptake of 18F-αvβ6-BP in lung damage will be measured by PET

  2. Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage

    Time frame: 3 months

    Uptake of 18F-αvβ6-BP in lung damage will be measured by PET

  3. Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage

    Time frame: 6 months

    Uptake of 18F-αvβ6-BP in lung damage will be measured by PET

Other outcomes

  1. Determine whether 18F-αvβ6-BP accumulation in lung correlates to lung damage as indicated on CT.

    Time frame: baseline

    Uptake of 18F-αvβ6-BP in lung measured by PET will be compared to lung damage as indicated on CT.

  2. Determine whether 18F-αvβ6-BP accumulation in lung correlates to lung damage as indicated on CT.

    Time frame: 3 months

    Uptake of 18F-αvβ6-BP in lung measured by PET will be compared to lung damage as indicated on CT.

  3. Determine whether 18F-αvβ6-BP accumulation in lung correlates to lung damage as indicated on CT.

    Time frame: 6 months

    Uptake of 18F-αvβ6-BP in lung measured by PET will be compared to lung damage as indicated on CT.

Sponsors and collaborators

Lead sponsor

University of California, Davis

Other

Registry information

Official study title

18F-αvβ6-binding-peptide PET/CT in Patients Post SARS CoV2 Infection

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
May 6, 2020
Registry last updated
Mar 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.